- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:30 | Diagonal Bio AB: Diagonal Bio AB publishes investment memorandum prior to upcoming rights issue of units | 56 | GlobeNewswire (Europe) | The subscription period of Diagonal Bio AB's ("Diagonal Bio" or the "Company") rights issue of units, which was resolved on 23 December 2024 by the Board of Directors together with the resolution on... ► Artikel lesen | |
| Fr | DIAGONAL BIO AB: Nomination Committee change in Diagonal Bio (publ.) | 2 | Cision News | ||
| Fr | Bulletin from the Extraordinary General Meeting of Diagonal Bio AB on 17 January 2025 | 2 | Cision News | ||
| Fr | XFRA CAPITAL ADJUSTMENT INFORMATION - 17.01.2025 | 105 | Xetra Newsboard | Das Instrument 2DV0 FR001400SVN0 DRONE VOLT SACA EO 1 EQUITY wird ex Kapitalmassnahme gehandelt am 17.01.2025 The instrument 2DV0 FR001400SVN0 DRONE VOLT SACA EO 1 EQUITY is traded ex capital adjustment... ► Artikel lesen | |
| 14.01. | DIAGONAL BIO AB: Diagonal Bio expands its testing panel for horses with EHV-5 detection | 1 | Cision News | ||
| 23.12.24 | DIAGONAL BIO AB: Diagonal Bio enters into a strategic partnership with Daniel Redén at StallZet to enhance commercialisation plans | 3 | Cision News | ||
| DIAGONAL BIO Aktie jetzt für 0€ handeln | |||||
| 22.11.24 | DIAGONAL BIO AB: Renowned horse race jockey and trainer conducts pilot test of LAMPlify® | 1 | Cision News | ||
| 18.11.24 | DIAGONAL BIO AB: Nomination Committee appointed for Diagonal Bio | 1 | Cision News | ||
| 13.11.24 | DIAGONAL BIO AB: Diagonal Bio announces pilot test with LAMPlify® at Kolgjini Stables | 1 | Cision News | ||
| 11.11.24 | Nasdaq Stockholm AB: Diagonal Bio AB receives observation status | 206 | GlobeNewswire | Today, on November 11, 2024, Diagonal Bio AB (the "Company") disclosed a press
release with information on the Company's financial situation.
The rules of Nasdaq First North Growth Market state that... ► Artikel lesen | |
| 11.11.24 | DIAGONAL BIO AB: Diagonal Bio announces that it is exploring financing options | 3 | Cision News | ||
| 31.10.24 | DIAGONAL BIO AB: Diagonal announces first pilot test at a stud with LAMPlify® | 4 | Cision News | ||
| 25.10.24 | DIAGONAL BIO AB: Diagonal Bio announces pilot test of LAMPlify® at Norwegian University of Life Sciences | 5 | Cision News | ||
| 22.10.24 | DIAGONAL BIO AB: Diagonal Bio will present LAMPlify® at a partnered event for trainers at Jägersro | 1 | Cision News | ||
| 11.10.24 | DIAGONAL BIO AB: Diagonal Bio announces successful external validation of LAMPlify® for viruses in pigs | 1 | Cision News | ||
| 08.10.24 | DIAGONAL BIO AB: Hunneberga Horse Stable to conduct pilot test of LAMPlify® | 2 | Cision News | ||
| 03.10.24 | DIAGONAL BIO AB: Horse trainer Daniel Redén at StallZet will conduct a pilot with LAMPlify® | 1 | Cision News | ||
| 02.10.24 | Diagonal Bio AB's warrant exercise registered at the Swedish Companies Registration Office | 2 | Cision News | ||
| 27.09.24 | Diagonal Bio AB announces the outcome of the exercise of warrants of series TO 1 | 1 | Cision News | ||
| 19.09.24 | DIAGONAL BIO AB: The last day of trading in warrants of series TO 1 is on the 24th of September 2024 | 2 | Cision News |
Seite:
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 9,764 | +2,31 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema | CAMBRIDGE, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,760 | +8,16 % | PACB Stock Declines Despite Promising HiFi Sequencing Findings | ||
| CENTOGENE | 0,100 | 0,00 % | Centogene NV: CENTOGENE Announces Voting Results of Extraordinary General Meeting | CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) ("CENTOGENE" or the "Company"), the essential life science partner for data-driven answers... ► Artikel lesen | |
| ATAI LIFE SCIENCES | 1,485 | +3,45 % | Atai Life Sciences Appoints Gerd Kochendoerfer As COO; Srinivas Rao Assumes Sole CEO Role | ||
| BIOMERIEUX | 113,80 | +0,71 % | Research and Markets: Europe Companion Diagnostics Market Analysis and Forecast, 2023-2033 with Competitive Analysis of Key Players - bioMerieux, F. Hoffmann-La Roche, ICON, and QIAGEN - ResearchAndMarkets.com | The "Europe Companion Diagnostics Market: Focus on Application, End User, Technology, and Country Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
The... ► Artikel lesen | |
| CYCLACEL | 0,340 | -2,58 % | Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs | BERKELEY HEIGHTS, N.J., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative... ► Artikel lesen | |
| SYROS PHARMACEUTICALS | 0,195 | -2,01 % | Kia India Begins Production of Syros SUV | Kia Syros SUV records 10,258 pre-orders, continuing impressive momentum following world premiere in December 2024New family-focused SUV specifically designed for customers in IndiaGroundbreaking... ► Artikel lesen | |
| GENUS | 20,800 | 0,00 % | Genus Sees H1 Adj. Profit Before Tax Ahead Of Expectations | LONDON (dpa-AFX) - Genus Plc (GNS.L), a biotechnology firm focused on animal genetics, said on Wednesday that it has recorded a strong performance for the first half and expects its earnings... ► Artikel lesen | |
| ANAPTYSBIO | 16,400 | +1,23 % | XFRA AN6: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 1,690 | +3,68 % | XTL BIOPHARMACEUTICALS LTD - 6-K, Report of foreign issuer | ||
| ABIONYX PHARMA | 1,208 | -3,05 % | ABIONYX Pharma Announces Its Financial Calendar for the Year 2025 | Regulatory News:
ABIONYX Pharma (FR0012616852 ABNX PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's... ► Artikel lesen | |
| MEIRAGTX | 6,100 | 0,00 % | MeiraGTx receives rare pediatric disease designation from FDA for its eye disease treatment | ||
| METABOLIC EXPLORER | 0,095 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 09.10.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 09.10.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 09.10.2024ISIN NameAU0000064966 VIRG.MON.... ► Artikel lesen | |
| AKESO | 7,500 | +5,63 % | Akeso, Inc.: Akeso Received Payment for the Development Collaboration on Tagitanlimab | HONG KONG, Jan. 22, 2025 /PRNewswire/ -- On January 22, 2025, Akeso Inc. (9926.HK) announced that it had received payment from Sichuan Kelun Pharmaceutical Research... ► Artikel lesen | |
| ISOFOL MEDICAL | 0,181 | +4,49 % | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January-September 2024 | GOTHENBURG, Sweden, November 12, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January-September 2024 is now available, in Swedish... ► Artikel lesen |
DIAGONAL BIO AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (-11,11 %) liegt der Kurs bei 0,002 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAGONAL BIO AB finden Sie auf Wallstreet Online.
